Literature DB >> 12591966

Hep par 1 antibody stain for the differential diagnosis of hepatocellular carcinoma: 676 tumors tested using tissue microarrays and conventional tissue sections.

Zhen Fan1, Matt van de Rijn, Kelli Montgomery, Robert V Rouse.   

Abstract

A well-characterized positive marker for hepatocellular differentiation would be a useful tool for the diagnosis of hepatocellular carcinoma (HCC). The recently commercially available Hep Par 1 antibody (clone OCH1E5.2.10) has been reported to be a sensitive marker for HCC in paraffin embedded sections. Of non-hepatocellular tumors, occasional carcinomas have been reported to stain, most frequently gastric adenocarcinomas. This study further evaluated the staining of this antibody on a large number of neoplasms using tissue microarray technology as well as conventional tissue sections. Six hundred seventy-six tumors, including 19 cases of HCC, were tested. Eighteen of 19 cases of HCC were positive, 3 showing <5% staining. Two cases negative on the array showed focal staining when whole tissue sections from the same tumors were used. 16 of 34 cases of gastric carcinomas gave positive reactions, 4 of these showed less than 5% staining. Staining of gastric carcinomas was not limited to signet ring-type carcinomas or to areas of hepatoid differentiation. Only 1 of 11 cases of cholangiocarcinoma showed focal staining. We also noted several other tumors to stain occasionally, including adrenal cortical carcinoma (3/13), yolk sac tumor (2/9), colonic adenocarcinoma (8/106), lung carcinoma (3/52), ovarian carcinoma (5/48), and endocervical adenocarcinoma (1/5). We did not observe staining in pancreatic carcinoma (11), renal cell carcinoma (36), breast carcinoma (85), melanoma (25), or mesothelioma (5). This study supports Hep Par 1 as a useful marker in the differential diagnosis of HCC, but with significant limitations. Cautious use of this antibody in a panel with other positive (alpha fetoprotein, CD10, polyclonal carcinoembryonic antigen) and negative (epithelial membrane antigen, monoclonal carcinoembryonic antigen, CD15) markers of hepatocellular differentiation may aid in the accurate diagnosis of HCC.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12591966     DOI: 10.1097/01.MP.0000052103.13730.20

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  48 in total

1.  Renal metastasis from primary hepatocellular carcinoma: a case report.

Authors:  Ryoken Yamanaka; Yohei Sekino; Takashi Babasaki; Hiroyuki Kitano; Kenichiro Ikeda; Keisuke Goto; Keisuke Hieda; Shogo Inoue; Tetsutaro Hayashi; Jun Teishima; Hiroshi Aikata; Kazuaki Chayama; Kazuhiro Sentani; Wataru Yasui; Akio Matsubara
Journal:  Int Cancer Conf J       Date:  2020-03-25

2.  My approach to the diagnosis of mesothelial lesions.

Authors:  K J Butnor
Journal:  J Clin Pathol       Date:  2006-06       Impact factor: 3.411

3.  Canalicular immunostaining of aminopeptidase N (CD13) as a diagnostic marker for hepatocellular carcinoma.

Authors:  C Röcken; J Licht; A Roessner; S Carl-McGrath
Journal:  J Clin Pathol       Date:  2005-10       Impact factor: 3.411

4.  Expression of both hepatocellular carcinoma and cholangiocarcinoma phenotypes in hepatocellular carcinoma and cholangiocarcinoma components in combined hepatocellular and cholangiocarcinoma.

Authors:  Mitsumaro Itoyama; Masaki Hata; Koji Yamanegi; Naoko Yamada; Hideki Ohyama; Hiroshi Hirano; Nobuyuki Terada; Keiji Nakasho
Journal:  Med Mol Morphol       Date:  2012-03-20       Impact factor: 2.309

5.  Expression of hepatocyte markers in mass-forming peripheral and periductal-infiltrating hilar intrahepatic cholangiocarcinomas.

Authors:  Hiroya Iida; Masaki Hata; Ayako Kakuno; Hiroshi Hirano; Koji Yamanegi; Naoko Yamada; Hideki Ohyama; Nobuyuki Terada; Chiaki Yasui; Naoki Yamanaka; Keiji Nakasho
Journal:  Oncol Lett       Date:  2011-09-02       Impact factor: 2.967

6.  Overexpression of CPS1 is an independent negative prognosticator in rectal cancers receiving concurrent chemoradiotherapy.

Authors:  Yi-Ying Lee; Chien-Feng Li; Ching-Yih Lin; Sung-Wei Lee; Ming-Jen Sheu; Li-Ching Lin; Tzu-Ju Chen; Ting-Feng Wu; Chung-Hsi Hsing
Journal:  Tumour Biol       Date:  2014-08-07

7.  High-level expression of divergent endodermal lineage markers in gonadal and extra-gonadal yolk sac tumors.

Authors:  Hadi Shojaei; Hong Hong; Raymond W Redline
Journal:  Mod Pathol       Date:  2016-07-22       Impact factor: 7.842

Review 8.  Clinicopathological characteristics in the differential diagnosis of hepatoid adenocarcinoma: a literature review.

Authors:  Jiann-Sheng Su; Yu-Tso Chen; Ren-Ching Wang; Chun-Ying Wu; Shou-Wu Lee; Teng-Yu Lee
Journal:  World J Gastroenterol       Date:  2013-01-21       Impact factor: 5.742

9.  Hepatoid adenocarcinoma of the stomach with liver metastasis mimicking hepatocellular carcinoma: a case report.

Authors:  Chih-Wen Lin; Chia-Chang Hsu; Hong-Cheng Chang; Yu-Chiun Sun; Po-Lin Sun; Chuan-Yan Hsu; Daw-Shyong Perng
Journal:  Cases J       Date:  2009-08-11

10.  A rare case of isolated duodenal metastases from hepatocellular carcinoma associated with p53 and ki-67 expression: a case report.

Authors:  Caroline Chung; Jaber Al Ali; David A Owen; Alan A Weiss; Eric M Yoshida; Isabella T Tai
Journal:  Cases J       Date:  2009-12-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.